LEXXNasdaqPharmaceutical PreparationsFiscal year ends August 31
Lexaria Bioscience Corp.
Financials through Q3 FY2026, quarter ended May 31, 2026Last filing: 10-Q on Jul 13, 2026
$2.60−0.26 (-9.09%)
Close on Oct 19, 2026
- Market cap
- $64.50M
- P/E (TTM)
- –
- Dividend yield
- –
Lexaria Bioscience statistics
Financials through May 31, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Lexaria Bioscience | Industry median |
|---|---|---|
| Market Cap | $64.45M | $166.30M |
| Enterprise Value | $60.41M | $87.12M |
| PS Ratio | 332.20 | 3.60 |
| PB Ratio | 13.60 | 2.03 |
| P/TBV Ratio | 14.65 | 2.31 |
Enterprise value
| Measure | Lexaria Bioscience | Industry median |
|---|---|---|
| EV / Sales | 311.40 | 2.43 |
Income (trailing twelve months)
| Measure | Lexaria Bioscience | Industry median |
|---|---|---|
| Revenue | $194.00K | $57.94M |
| Gross Profit | $194.00K | $90.47M |
| Operating Income | -$7.71M | -$21.49M |
| Net Income | -$7.73M | -$22.46M |
| EBITDA | -$7.68M | -$17.14M |
| EPS (Diluted) | -$0.35 | -$0.83 |
Margins
| Measure | Lexaria Bioscience | Industry median |
|---|---|---|
| Gross Margin | 100.0% | 52.3% |
| Operating Margin | -3973.2% | -44.5% |
| Profit Margin | -3985.6% | -39.2% |
| EBITDA Margin | -3960.4% | -31.3% |
| FCF Margin | -3848.6% | -8.85% |
Returns
| Measure | Lexaria Bioscience | Industry median |
|---|---|---|
| Return on Equity (ROE) | -150.3% | -53.2% |
| Return on Assets (ROA) | -134.2% | -41.0% |
| Return on Invested Capital (ROIC) | -602.0% | -32.2% |
| Return on Capital Employed (ROCE) | -175.3% | -38.0% |
Growth
| Measure | Lexaria Bioscience | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -68.5% | 6.01% |
| Revenue Growth (3Y CAGR) | 40.3% | 2.25% |
| Revenue Growth (5Y CAGR) | 17.5% | 6.42% |
Balance sheet
| Measure | Lexaria Bioscience | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $3.64M | $62.64M |
| Net Cash (Debt) | $3.64M | $15.77M |
| Net Cash Per Share | $0.15 | $0.66 |
| Equity (Book Value) | $4.74M | $48.61M |
| Book Value Per Share | $0.19 | $1.36 |
| Tangible Book Value | $4.40M | $23.01M |
| Working Capital | $3.68M | $75.09M |
Financial position
| Measure | Lexaria Bioscience | Industry median |
|---|---|---|
| Current Ratio | 10.60 | 3.30 |
| Quick Ratio | 9.63 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Lexaria Bioscience | Industry median |
|---|---|---|
| Operating Cash Flow | -$7.43M | -$12.39M |
| Capital Expenditures | -$40.82K | -$1.07M |
| Free Cash Flow | -$7.47M | -$20.34M |
| FCF Per Share | -$0.30 | -$0.42 |
Efficiency
| Measure | Lexaria Bioscience | Industry median |
|---|---|---|
| Asset Turnover | 0.03 | 0.38 |
| Revenue Per Employee | $1.45K | $398.96K |
| Profits Per Employee | -$57.70K | -$705.27K |
| Employee Count | 134 | 74 |
Dividends and yields
| Measure | Lexaria Bioscience | Industry median |
|---|---|---|
| Earnings Yield | -12.0% | -22.8% |
| FCF Yield | -11.6% | -9.02% |
| Buyback Yield | -10.1% | -0.73% |
| Shareholder Yield | -10.1% | 0.00% |
Shares
| Measure | Lexaria Bioscience | Industry median |
|---|---|---|
| Shares Outstanding | 24,787,400 | 58,139,000 |
| Shares Change (YoY) | 32.3% | 11.1% |
| Shares Change (QoQ) | -0.40% | 0.54% |
| Float | 24,053,700 | 49,154,900 |
| Shares Held by Insiders | 2.96% | 11.6% |
Scores
| Measure | Lexaria Bioscience | Industry median |
|---|---|---|
| Altman Z-Score | 64.06 | -0.27 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Lexaria Bioscience's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.